ProductNum | picture | CAS No. | Name and description | Formula | Quick order |
---|---|---|---|---|---|
CL2320 |
|
54350-48-0 |
Etretinate (Ro 10-9359) 98+% |
C23H30O3 | |
CLA1312 |
|
945781-29-3 |
Placulumab 95+% |
— | |
CLA1294 |
|
1228538-47-3 |
Quilizumab 95+% |
— | |
CLA1286 |
|
1143503-67-6 |
Tabalumab (Anti-TNFSF13B / BAFF / CD257) 95+% |
— | |
CLA1283 |
|
1167985-17-2 |
Ozoralizumab 95+% |
— | |
CLA1263 |
|
1062149-33-0 |
Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266) 95+% |
— | |
CLA1252 |
|
912628-39-8 |
Drozitumab (Anti-TNFRSF10B / TRAILR2 / CD262) 95+% |
— | |
CLA1229 |
|
162774-06-3 |
Nerelimomab 95+% |
— | |
CLA1190 |
|
640735-09-7 |
Anti-Human CD30 Monoclonal Antibody(Iratumumab) 95+% |
— | |
CLA1171 |
|
896731-82-1 |
Conatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) 95+% |
— | |
CLA1148 |
|
845816-02-6 |
Lexatumumab 95+% |
— | |
CLA1143 |
|
903512-50-5 |
Lucatumumab (Synonyms: HCD122) 95+% |
— | |
CLA1142 |
|
476181-74-5 |
Golimumab 95+% |
— | |
CLA1103 |
|
156227-98-4 |
Afelimomab 95+% |
— | |
CLA1060 |
|
267227-08-7 |
Apolizumab 95+% |
— | |
CLA1059 |
|
220651-94-5 |
Ruplizumab 95+% |
— | |
CL2185 |
|
987-78-0 |
Citicoline 98+% |
C14H26N4O11P2 | |
CL2179 |
|
11041-94-4 |
Higenamine hydrochloride 98+% |
C16H18ClNO3 | |
CL2163 |
|
152946-68-4 |
Nolatrexed dihydrochloride 98+% |
C14H14Cl2N4OS | |
CL2013 |
|
1346547-00-9 |
GSK583 98+% |
C20H19FN4O2S | |